一种靶向炎症和瘙痒相关介质的非甾体新型制剂可调节实验性过敏性接触性皮炎。
A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis.
作者信息
Gordon William C, López Virginia García, Bhattacharjee Surjyadipta, Gil David Rodríguez, Díaz Javier Alcover, de la Losa Fernando Pineda, Peláez Ricardo Palacios, Ferrer Concha Tiana, Bacchini Gabriela Silvina, Jun Bokkyoo, Varoqui Hélène, Bazan Nicolas G
机构信息
Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Diater, Av. Gregorio Peces Barba, Madrid, Spain.
出版信息
Dermatol Ther (Heidelb). 2018 Mar;8(1):111-126. doi: 10.1007/s13555-018-0223-8. Epub 2018 Feb 16.
INTRODUCTION
A major clinical challenge in treating allergic contact dermatitis (ACD) is that the first line of treatment is based on the use of corticosteroids. In this study, we aimed to develop a formulation that is devoid of steroids.
METHODS
We used mouse ears treated with dinitrofluorobenzene (DNFB) to induce ACD. The efficacy of the test formulation to ameliorate and to prevent induced ACD was determined.
RESULTS
To treat this experimentally induced ACD, we developed a formulation containing BIPxine (a mixture of Rosa moschata and Croton lechleri (antioxidants) and Aloe vera and D-panthenol (moisturizers), and hydroglycolic solutions of disodium cromoglycate. Our results show that clear inhibition of ACD took place. The target of this formulation was PAR-2, TRPV4, and other mediators of the inflammatory and pain responses. However, this formulation must be evaluated in other models besides the mouse to confirm its effectiveness.
CONCLUSION
The formulation presented here may provide new ACD therapies that do not involve the use of corticosteroids.
引言
治疗过敏性接触性皮炎（ACD）的一个主要临床挑战是一线治疗基于使用皮质类固醇。在本研究中，我们旨在开发一种不含类固醇的制剂。
方法
我们使用经二硝基氟苯（DNFB）处理的小鼠耳朵来诱导ACD。测定了测试制剂改善和预防诱导性ACD的功效。
结果
为了治疗这种实验诱导的ACD，我们开发了一种制剂，其包含BIPxine（麝香蔷薇和巴豆提取物（抗氧化剂）、库拉索芦荟和D-泛醇（保湿剂）的混合物）以及色甘酸二钠的水醇溶液。我们的结果表明对ACD有明显抑制作用。该制剂的作用靶点是蛋白酶激活受体-2（PAR-2）、瞬时受体电位香草酸亚型4（TRPV4）以及炎症和疼痛反应的其他介质。然而，除了小鼠模型外，该制剂还必须在其他模型中进行评估以确认其有效性。
结论
本文提出的制剂可能提供不涉及使用皮质类固醇的新的ACD治疗方法。
Zotero 插件